Browse > Article

Neuroprotective Effect of a Novel Herbmedicine, Hepad on SH-SY5Y Cells  

Kim, Eun Hye (Department of Biomedical Laboratory Science, School of Medicine, Eulji University)
Park, Byung-Jun (Young Jin Korea Medical Clinic)
Kim, Jung Seok (Department of Biomedical Laboratory Science, School of Medicine, Eulji University)
Kim, Dong-Hee (Department of Pathology, College of Oriental Medicine, Daejeon University)
Choi, Hak Joo (Department of Pathology, College of Oriental Medicine, Daejeon University)
Kim, In Sik (Department of Biomedical Laboratory Science, School of Medicine, Eulji University)
Publication Information
Biomedical Science Letters / v.19, no.1, 2013 , pp. 79-82 More about this Journal
Abstract
Parkinson's disease is a neurodegenerative disease with a wide range of dopaminergic neuron cell death in the substantia nigra. Oxidative stress and neural degeneration are suggested to be involved in the pathogenesis of Parkinson's disease. In this study, we investigated whether a novel herbmedicine, Hepad protects against 1-methyl-4-phenylpyridnium [MPP(+)]-induced dopaminergic neurotoxicity in SH-SY5Y cells. We found that pretreatment with Hepad significantly increases the proliferation of SH-SY5Y cells (P<0.05) and reversed the loss of cell viability induced by $MPP^+$. Hepad may be a promising neuroprotective agent for the treatment of neurodegenerative disorders such as Parkinson's disease.
Keywords
Parkinson's disease; Hepad; SH-SY5Y cells; Cytotoxicity;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, Horak FB, Okun MS, Foote KD, Krack P, Pahwa R, Henderson JM, Hariz MI, Bakay RA, Rezai A, Marks WJ Jr, Moro E, Vitek JL, Weaver FM, Gross RE, DeLong MR. Deep brain stimulation for parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011. 68: 165.
2 Dauer W, Przedborski S. Parkinson' disease: mechanisms and models. Neuron 2003. 39: 889-909.   DOI   ScienceOn
3 de Lau LM, Breteler MM. Epidemiology of parkinson's disease. Lancet Neurol. 2006. 5: 525-535.   DOI   ScienceOn
4 Jain S, Wood NW, Healy DG. Molecular genetic pathways in parkinson's disease: a review. Clin Sci (Lond). 2005. 109: 355-364.   DOI   ScienceOn
5 Kidd PM. Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern Med Rev. 2000. 5: 502-529.
6 Park BJ, Kim DH. A study on a case of treatment termination of parkinson's disease treated by 5 upright life cure regulations therapy. Institute of Oriental medicine of Dajeon University J. 2011. 19: 57-64.
7 Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of parkinson's disease. Mov Disord. 2001. 16: 507-510.   DOI   ScienceOn
8 Zhang ZG, Wu L, Wang JL, Yang JD, Zhang J, Zhang J, Li LH, Xia Y, Yao LB, Qin HZ, Gao GD. Astragaloside IV prevents $MPP^+$-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production. Mol Cell Biochem. 2012. 364: 209-216.   DOI   ScienceOn
9 Blandini F, Armentero MT. Animal models of parkinson's disease. FEBS J. 2012. 279: 1156-1166.   DOI
10 Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in parkinson's disease. Prog Neurobiol. 2001. 65: 135-172.   DOI   ScienceOn